Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
about
Laquinimod in the treatment of multiple sclerosis: a review of the data so farRemyelination Therapy in Multiple SclerosisRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesGlobal and regional annual brain volume loss rates in physiological aging.Clinical relevance of brain volume measures in multiple sclerosis.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.Laquinimod in the treatment of relapsing remitting multiple sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.Role and therapeutic value of dendritic cells in central nervous system autoimmunity.Oral disease-modifying therapies for multiple sclerosis.Defining Disease Activity and Response to Therapy in MS.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple SclerosisLaquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorEvaluating response to disease-modifying therapy in relapsing multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials - Commentary.Predictive value of early brain atrophy on response in patients treated with interferon βEffect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.Imaging outcome measures for progressive multiple sclerosis trialsLaquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake.Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model.A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.Occulomotor Neural Integrator Dysfunction in Multiple Sclerosis: Insights From Neuroimaging
P2860
Q26752895-EB0C91AC-54D6-4772-B62F-F2F80616E67FQ26772359-44DA4AC0-6C05-4001-8FDE-5CF42593060FQ28082878-E315DA9C-C8D3-486F-8032-8E45F5125393Q29030703-00669B09-FB96-436E-AA1D-148CDD91B3C5Q30490628-4A8B19CB-5D68-4C71-92BF-DA040CB296C1Q30738659-EA89C4CC-8AF4-4207-9F33-2F0BB4A32146Q30869048-CC6AD6E7-D41B-4456-B43C-0CE3F8AF47F0Q31015218-2CE6F032-CDAC-423F-B0FD-4BAFCBD1B4ACQ31080085-E4F3DD3B-CCE8-41A0-8304-E94CCD6A5C0DQ31160866-7B6C2EB6-466D-458D-B9EF-2B1946930D00Q33634866-9D8DC880-FE3F-4311-ACE3-5EF1DE8F0787Q34286754-36BC5AE4-3DFD-4324-B10A-CB70F494951AQ34332609-3867D261-3933-46DE-BDA3-612BE10E1DC5Q34924088-7DAEFCFC-67A7-440D-A390-935DCEE858F4Q34996562-86DE3FA9-BD13-40AB-8A8B-02639A237D2BQ36357501-7E61D7EE-488D-4C67-BCD9-B0700B5472CFQ37169655-B92C59F4-E87E-4592-A3F9-08F3A31F81A0Q37320255-7798E56F-2E61-488C-8619-B6FE84DE2D24Q37346761-6F9F6089-1D1A-4BF1-B527-D9C713A03F46Q38375605-9A83A11E-5EE0-45E4-8011-FC5C66EDA677Q38534132-8B0483D1-5945-40A5-8297-5F2D778E8519Q38639337-2B7F1A12-DBC2-427E-8EBB-D250F979B821Q38664610-B18F92F2-293D-40CF-B19C-8092567D9075Q41197913-2D367AE4-DC40-42D7-9A6E-998AC45D6B8EQ41647429-F296538F-98B9-4B27-9F4D-FB3DB520FAC9Q42660399-9D2E19B2-7D3D-408D-9C9B-671DAEF4461BQ47211013-4361B3E9-1EE9-4CD7-B495-A82F8D2A686AQ47695368-1A96A6E2-88B2-4383-B1E9-3FF09D121400Q48770738-34F9B5B3-5CC9-4CD1-9272-EF5B6B3F66FCQ50557509-0216DC0C-7655-4AD4-948D-02FCBEA91057Q51822950-7363966E-838B-401E-B185-C875FD55561AQ55428811-07BA449B-1EA3-43DE-AEEA-04F93BED9702Q55502196-66D05697-1573-4A23-9367-62E64E342055Q58712339-5C28D22D-3D38-4B08-9932-7E90F3E9C2A1
P2860
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Placebo-controlled trial of or ...... effect on brain tissue damage.
@en
type
label
Placebo-controlled trial of or ...... effect on brain tissue damage.
@en
prefLabel
Placebo-controlled trial of or ...... effect on brain tissue damage.
@en
P2093
P2860
P50
P356
P1476
Placebo-controlled trial of or ...... effect on brain tissue damage.
@en
P2093
Alexei N Boyko
Douglas Jeffery
Elisabetta Pagani
Xavier Montalban
P2860
P304
P356
10.1136/JNNP-2013-306132
P407
P577
2013-09-12T00:00:00Z